A weekly dipeptidyl peptidase-4 (DPP-4) inhibitor was just as effective at controlling type 2 diabetic patients’ blood sugar as a daily DPP-4 inhibitor in a recent randomized clinical trial.
A weekly dipeptidyl peptidase-4 (DPP-4) inhibitor was just as effective at controlling type 2 diabetic patients’ blood sugar as a daily DPP-4 inhibitor in a recent randomized clinical trial.
The drug, called omarigliptin, offers the prospect of a more convenient treatment for patients with diabetes.
“The observed glycaemic efficacy in the present study indirectly serves as further evidence of the feasibility of providing DPP-4 inhibition over the period of 1 week with a single once-weekly dose that is similar to that which can be achieved with daily administration,” wrote the authors of the Diabetes, Obesity and Metabolism study.
Additional Information:
Link to study: http://onlinelibrary.wiley.com/doi/10.1111/dom.12832/abstract
About Journal
Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics is the only interdisciplinary journal for high-quality research and reviews in the areas of diabetes, obesity and metabolism. It focuses on clinical and experimental pharmacology and therapeutics in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems.
Penny Smith-
+44 (0)1243 770171
sciencenewsroom@wiley.com